Draupnir Bio

Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society. We are establishing ourselves at the forefront of protein degradation. At Draupnir, our differentiated platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas of unmet therapeutic need. Our team at Draupnir Bio is driven by a deep commitment to scientific excellence, and by the desire to bring innovative therapies to patients. Draupnir Bio is a spin out from Aarhus University and the Max-Planck Society based on the breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger. Draupnir Bio expands research operations with new R&D facility at INCUBA research park. Draupnir Bio funded by a 30 M EUR series A investment by Novo Seeds, Gilde Healthcare Partners, INKEF Capital and High-Tech Gründerfonds. Draupnir Bio founded with investment from founders and grant from the Novo Nordisk Foundation.